Gemphire Therapeutics Inc (GEMP) - Financial and Strategic SWOT Analysis Review

  • ID: 4282077
  • SWOT Analysis
  • 46 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Apotex Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Lupin Pharmaceuticals Inc
  • Merck & Co Inc
  • Mylan NV
  • MORE
Gemphire Therapeutics Inc (GEMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Gemphire Therapeutics Inc (Gemphire), formerly Michigan Life Therapeutics LLC, is a clinical stage biopharmaceutical company that develops and commercializes therapies for patients with cardiometabolic disorders, including dyslipidemia and non-alcoholic steatohepatitis (NASH). Its lead product, Gemcabene (CI-1027), which is licensed from Pfizer is an oral therapy that targets known lipid metabolic pathways, lowering levels of LDL-C, inflammation and triglycerides. The company is evaluating gemcabene in clinical trials to enhance the clearance of very low-density lipoproteins (VLDLs) and to and inhibit the production of fatty acids and cholesterol in the liver. Gemphire is headquartered in Livonia, Michigan, the US.

Gemphire Therapeutics Inc Key Recent Developments

May 08, 2018: Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 03, 2018: Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer
Mar 15, 2018: Gemphire Therapeutics Announces Fourth Quarter And Fiscal Year 2017 Financial Results
Nov 13, 2017: Gemphire Therapeutics Reports Third Quarter 2017 Financial Results
Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Apotex Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Lupin Pharmaceuticals Inc
  • Merck & Co Inc
  • Mylan NV
  • MORE
Section 1 - About the Company
  • Gemphire Therapeutics Inc - Key Facts
  • Gemphire Therapeutics Inc - Key Employees
  • Gemphire Therapeutics Inc - Key Employee Biographies
  • Gemphire Therapeutics Inc - Major Products and Services
  • Gemphire Therapeutics Inc - History
  • Gemphire Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Gemphire Therapeutics Inc - Business Description
  • Gemphire Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Gemphire Therapeutics Inc - Strengths
  • Gemphire Therapeutics Inc - Weaknesses
  • Gemphire Therapeutics Inc - Opportunities
  • Gemphire Therapeutics Inc - Threats
  • Gemphire Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Gemphire Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2018: Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
  • May 03, 2018: Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer
  • Nov 13, 2017: Gemphire Therapeutics Reports Third Quarter 2017 Financial Results
  • Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update
  • May 30, 2017: Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch
  • May 09, 2017: Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update
  • May 04, 2017: Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape
  • Mar 29, 2017: Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 15, 2017: Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Gemphire Therapeutics Inc, Key Facts
  • Gemphire Therapeutics Inc, Key Employees
  • Gemphire Therapeutics Inc, Key Employee Biographies
  • Gemphire Therapeutics Inc, Major Products and Services
  • Gemphire Therapeutics Inc, History
  • Gemphire Therapeutics Inc, Key Competitors
  • Gemphire Therapeutics Inc, Ratios based on current share price
  • Gemphire Therapeutics Inc, Annual Ratios
  • Gemphire Therapeutics Inc, Annual Ratios
  • Gemphire Therapeutics Inc, Interim Ratios
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Gemphire Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Gemphire Therapeutics Inc, Performance Chart (2013 - 2017)
  • Gemphire Therapeutics Inc, Ratio Charts
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Mylan NV
  • Merck & Co Inc
  • Lupin Pharmaceuticals Inc
  • Intercept Pharmaceuticals Inc
  • Eli Lilly and Co
  • AstraZeneca Plc
  • Apotex Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll